Ashling Wahner

Off-the-shelf mosunetuzumab/polatuzumab vedotin produced durable responses with manageable safety in BTK inhibitor–exposed relapsed/refractory MCL.

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.

Panitumumab plus FOLFIRINOX or mFOLFOX6 failed to yield meaningful responses in liver-limited, RAS/BRAF wild-type unresectable mCRC.

Irpagratinib plus atezolizumab showed durable responses and manageable safety in advanced HCC with FGF19 overexpression, regardless of prior ICI exposure.

SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.

Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.

Authors noted that BiTEs have expanded the treatment paradigms for several types of solid tumors and blood cancers; however, toxicities associated with this class of agents have raised safety concerns.

VXM01 plus avelumab was tolerable and could potentially produce clinically meaningful responses in patients with recurrent glioblastoma.

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer.

Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world findings.

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.

The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.

T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.

While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.

Pembrolizumab, added to preoperative radiation and surgery, prolonged disease-free survival in patients with soft tissue sarcoma of the extremity.

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant.

NCCN guidelines now recommend ctDNA testing for MRD assessment for patients with PET-positive DLBCL after treatment.

Frontline treatment with belzutifan and cabozantinib resulted in durable responses and a manageable safety profile in patients with previously untreated advanced ccRCC.

Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy.

Meta: Blinatumomab plus chemotherapy, vs chemotherapy alone, significantly improved DFS rates and was well tolerated in pediatric patients with standard-risk pediatric B-ALL.

Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer compared to placebo, showing significant clinical benefits.

The FDA approved a companion diagnostic to identify patients with biliary tract cancer eligible for treatment with zanidatamab.

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated melanoma.